Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lemaitre Vascular (LMAT) EBITDA (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed EBITDA for 16 consecutive years, with $18.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 46.51% to $18.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $67.9 million through Dec 2025, up 29.96% year-over-year, with the annual reading at $67.9 million for FY2025, 29.96% up from the prior year.
  • EBITDA for Q4 2025 was $18.8 million at Lemaitre Vascular, down from $20.3 million in the prior quarter.
  • The five-year high for EBITDA was $20.3 million in Q3 2025, with the low at $5.8 million in Q2 2022.
  • Average EBITDA over 5 years is $11.0 million, with a median of $9.8 million recorded in 2023.
  • The sharpest move saw EBITDA soared 127.96% in 2021, then crashed 47.92% in 2022.
  • Over 5 years, EBITDA stood at $8.3 million in 2021, then fell by 16.07% to $7.0 million in 2022, then surged by 46.49% to $10.2 million in 2023, then rose by 25.95% to $12.9 million in 2024, then skyrocketed by 46.51% to $18.8 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $18.8 million, $20.3 million, and $16.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.